[
  {
    "ts": null,
    "headline": "Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek",
    "summary": "The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.",
    "url": "https://finnhub.io/api/news?id=0287a80b570ce2e587c5c8ff0c162fb1c89dba5ab454a2cfc3010a83d0809725",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734979440,
      "headline": "Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek",
      "id": 132123050,
      "image": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.",
      "url": "https://finnhub.io/api/news?id=0287a80b570ce2e587c5c8ff0c162fb1c89dba5ab454a2cfc3010a83d0809725"
    }
  },
  {
    "ts": null,
    "headline": "Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13",
    "summary": "Vertex Pharmaceuticals Incorporated today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...",
    "url": "https://finnhub.io/api/news?id=18a4be297cf888d7df014a999409c6612a89f6ae585bcd12c153b0b110499807",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734969963,
      "headline": "Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13",
      "id": 132122951,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Incorporated today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...",
      "url": "https://finnhub.io/api/news?id=18a4be297cf888d7df014a999409c6612a89f6ae585bcd12c153b0b110499807"
    }
  },
  {
    "ts": null,
    "headline": "Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings",
    "summary": "Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.",
    "url": "https://finnhub.io/api/news?id=0c59904bab750294a6b6a33839bbfd40ed9f80e17c37a28415f8ed16d952bb12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734957556,
      "headline": "Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings",
      "id": 132118176,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2375295861-e1734953365392.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.",
      "url": "https://finnhub.io/api/news?id=0c59904bab750294a6b6a33839bbfd40ed9f80e17c37a28415f8ed16d952bb12"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis...",
    "url": "https://finnhub.io/api/news?id=0cc1317eadcb1504d9209b008edccae8b5ff5652f119c9af39c4f40fb1cfba05",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734953199,
      "headline": "Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 132120314,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis...",
      "url": "https://finnhub.io/api/news?id=0cc1317eadcb1504d9209b008edccae8b5ff5652f119c9af39c4f40fb1cfba05"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
    "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration has approved the expanded use of TRIKAFTA for the treatment of people with cystic fibrosis ages 2...",
    "url": "https://finnhub.io/api/news?id=bea9620375072e454a58735183c5f31dcbbf82d6d2361021bbb41ec79f110357",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734953198,
      "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
      "id": 132120317,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration has approved the expanded use of TRIKAFTA for the treatment of people with cystic fibrosis ages 2...",
      "url": "https://finnhub.io/api/news?id=bea9620375072e454a58735183c5f31dcbbf82d6d2361021bbb41ec79f110357"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734930900,
      "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
      "id": 132116815,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827"
    }
  }
]